Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Mark Pomerantz is a medical oncologist at the Dana-Farber Cancer Institute. Dr. Pomerantz received his undergraduate degree from Yale University and his medical degree from Stanford University. He trained in Internal Medicine at Brigham and Women's Hospital in Boston, Massachusetts. He then pursued a fellowship in Medical Oncology at the Dana-Farber Cancer Institute in Boston. Dr. Pomerantz received his post-doctroal training in cancer genetics with Dr. Matthew Freedman at the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT. He is on faculty at the Dana-Farber Cancer Institute in the Lank Center for Genitourinary Oncology.
Inherited risk of cancer and genetic determinants disease outcome
Dr. Pomerantz's research focuses on the factors associated with cancer risk, with an emphasis on prostate cancer. Prostate cancer develops in the setting of many environmental and inherited risk factors. Since 2006, the inherited component of the disease has come into clearer focus. Multiple genetic markers, inherited from one's parents and highly associated with risk of prostate cancer, have been discovered. However, the mechanism in which these inherited factors predispose one to disease is unknown. Working closely with clinicians, biostatisticians and epidemiologists at Dana-Farber and the Broad Institute, he is actively deciphering this mechanism in an attempt to define the underpinnings of prostate cancer risk.
Dana-Farber Cancer Institute450 Brookline AvenueDana 1230Boston, MA 02215Get Directions